Statistics from Altmetric.com
QUESTION: In women of reproductive age, is the levonorgestrel releasing (20 μg/d) intrauterine system (LNG-20) more effective and tolerable than other reversible contraceptive methods?
Studies were identified using Medline, EMBASE/Excerpta Medica, PsycLIT, POPLINE, Cochrane Controlled Trials Register, and specialist databases between January 1974 and July 1998. Bibliographies of relevant articles were also reviewed. Experts in the field and organisations were contacted for unpublished data.
Randomised controlled trials were selected if participants were women of reproductive age, they compared LNG-20 with another reversible contraceptive, and they had predetermined outcomes.
Data were extracted on predetermined outcomes of pregnancy as a result of method or user failure and continuation of contraceptive method. Data on these outcomes were extracted when either number of events per women months or single decrement life table probabilities were reported.
5 studies met the inclusion criteria. LNG-20 was compared with 2 groups of intrauterine devices (IUDs), categorised by the surface area of the copper wire: ≤250 mm2 (Nova-T, CuT 200, and CuT 220 IUDs) and >250 mm2 (CuT 380 Ag IUD). At 5 years of follow up, LNG-20 was more effective than IUDs ≤250 mm2 for preventing unplanned pregnancy (rate ratio [RR] 0.08, 95% CI 0.04 to 0.18) but not more effective than IUDs >250 mm2 (RR 0.66, CI 0.25 to 1.75) (table). Overall, continued use was more likely with LNG-20 than with IUDs ≤250 mm2 (RR 1.16, CI 1.02 to 1.31) and equally as likely with IUDs >250 mm2 (RR 0.97, CI 0.83 to 1.14) (table). LNG-20 users were more likely to discontinue use because of hormonal side effects than were users of IUDs ≤250 mm2 (RR 5.2, CI 1.3 to 20.3) and IUDs >250 mm2 (RR 4.2, CI 2.0 to 9.0). LNG-20 users were also more likely to discontinue use because of amenorrhea than were users of IUDs ≤250 mm2 (RR 29.2, CI 1.7 to 488) and IUDs >250 mm2 (RR 48.9, CI 16.9 to 141).
In women of reproductive age, the levonorgestrel releasing (20 μg/d) intrauterine system (LNG-20) is more effective than intrauterine devices (IUDs) ≤ 250 mm2 but as effective as IUDs >250 mm2 for preventing pregnancy. LNG-20 is more likely to lead to discontinued use because of hormonal side effects and amenorrhea.
The systematic review by French et al addresses an important clinical question. The study methods reported were appropriate, and the search for relevant studies was comprehensive. The willingness by volunteers to be randomly allocated, however, implies that either contraceptive method was acceptable. The copper IUD comparative studies would therefore be unlikely to include women with heavy or painful menses, who are most likely to benefit from the “side effects” of LNG-20 (ie, reduction of menstrual flow and pain). Some studies also noted the importance of pre-insertion counselling to reduce concern about amenorrhea or the occurrence of irregular bleeding in the early months of use.
The category of IUDs ≤250 mm2 could be misleading because the only studies that were analysed related to the CuT 380 Ag IUD, which has copper on the side arms and in the centre. No available comparisons existed with other high copper load devices positioned only centrally (eg, Multiload 375). The distinction in the positioning of the copper may be one reason why the CuT 380 Ag IUD has such low pregnancy rates.
This review has a broader title than that of the abstract because a search was made for comparison with all reversible methods. Only 1 study not using a copper IUD was identified as eligible. This was a 3 year comparison with Norplant 2 that involved only 200 women and found no significant difference in measured outcomes other than fewer removals of devices because of bleeding with LNG-20.
The LNG-20 and the CuT 380 Ag IUD are equally effective and acceptable for women with normal menses. Questions remaining include which women are likely to benefit from a specific choice of 1 device or the other and the issue of cost effectiveness.
Source of funding: NHS R&D Health Technology Assessment Programme.
For correspondence: Dr R French, Department of Sexually Transmitted Diseases, Royal Free and University College Medical School, Mortimer Market Centre, off Capper Street, London WC1E 6AU, UK. Fax + 44 (0)207 679 9669.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.